UMN-0502 is seasonal influenza vaccine manufactured using a baculovirus to grow three kinds of hemagglutinins in insect cells, with a combination of recombinant DNA technology. A cell-based influenza vaccine offers key advantages over influenza vaccines manufactured using older traditional production methods such as speed, safety and cost effectiveness.
Phase I/II clinical trials were conducted by Astellas Pharma Inc. in Japan with favorable immunogenicity and tolerability observed in 2011. Phase III clinical trials are under preparation with Astellas Pharma Inc. with the aim of being commenced in the second half of 2012.
Protein Sciences Corporation is developing the same novel seasonal influenza vaccine as UMN-0502 in the United States called FluBlok. FluBlok has successfully completed Phase III clinical trials and is awaiting formal marketing approval from the Food and Drug Administration.
UMN holds exclusive rights from Protein Sciences Corporation to commercialize influenza vaccines in Asian countries such as Japan, China, Hong Kong, Korea, Singapore and Taiwan. UMN is actively negotiating with several local pharmaceutical and vaccine companies in those countries.

UMN-0501 is a pandemic influenza vaccine manufactured using a baculovirus to grow H5N1 hemagglutinin in insect cells, with a combination of recombinant DNA technology. A cell-based influenza vaccine offers key advantages over influenza vaccines manufactured using older traditional production methods such as speed, safety and cost effectiveness. Phase I/II clinical trials have been successfully completed with both immunogenicity and safety confirmed. Results were presented in February of 2008 at the World Health Organization‘s 5th Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials.　UMN-0501 was granted orphan drug status in May of 2008 in Japan. UMN's influenza program was licensed from Protein Sciences Corporation in the United States. Astellas Pharma Inc. conducted Phase II clinical trial under their own project code number ASP7373 in 2011.
UMN has entered into negotiations with several local pharmaceutical and vaccine companies in China, Hong Kong, Korea, Singapore and Taiwan.

UMN-0901 is a pandemic influenza vaccine manufactured using a baculovirus to grow the H9N2 hemagglutinin in insect cells, with a combination of recombinant DNA technology. H9N2 influenza virus is endemic in many Asian countries and is regarded as a candidate for the next human pandemic. We are currently executing nonclinical studies and planning phase I/II clinical trials in Japan.

UMN-2003 is a norovirus VLP + rotavirus VP6 non-live injectable trivalent vaccine for the prevention of two major causative agents of acute gastroenteritis in one injection. The norovirus VLP + rotavirus VP6 combination vaccine is proven to be highly immunogenic in mice and the combination does not interfere, but rather potentiates the immune response of each component. We are currently executing nonclinical studies and are planning phase I/II clinical trials in Finland.